Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms

Carminati, Giuliana Galli; Deriaz, Nicolas; Bertschy, Gilles

doi:10.1016/j.pnpbp.2005.10.002

Cited by 47 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carminati, Deriaz and Bertschy [86] had good experiences with venlafaxine in the treatment of SIB and ADHD-like symptoms in patients with pervasive developmental disorders. This review highlights the need for clinicians to recognise the ADHD population as being at increased risk of self-harm.…”

Section: Discussionmentioning

confidence: 99%

The association of ADHD symptoms to self-harm behaviours: a systematic PRISMA review

Allely

2014

BMC Psychiatry

View full text Add to dashboard Cite

BackgroundSelf-harm is a major public health issue in young people worldwide and there are many challenges to its management and prevention. Numerous studies have indicated that ADHD is associated with completed suicides and other suicidal behaviours (i.e., suicidal attempt and ideation). However, significantly less is known about the association between ADHD and self-harm.MethodThis is the first review of the association between ADHD and self-harm. A systematic PRISMA review was conducted. Two internet-based bibliographic databases (Medline and CINAHL) were searched to access studies which examined to any degree the association between, specifically, ADHD and self-harm.ResultsOnly 15 studies were identified which investigated the association between ADHD and self-harm and found evidence to support that ADHD is a potential risk factor for self-harm.ConclusionThis association raises the need for more awareness of self-harm in individuals with symptoms of ADHD.

show abstract

Section: Discussionmentioning

confidence: 99%

The association of ADHD symptoms to self-harm behaviours: a systematic PRISMA review

Allely

2014

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…The subject exhibited increased agitation. In a recent case series of three subjects (ages 17-23 years) with autism [71], all subjects showed improvement on venlafaxine (18.75 mg/ day). The medication was well tolerated.…”

Section: Other Antidepressants Venlafaxinementioning

confidence: 96%

Recent Advances in the Pharmacological Treatment of Pervasive Developmental Disorders

Moussavand

Findling

2007

CPR

View full text Add to dashboard Cite

Introduction. There is growing body of evidence to suggest that pharmacotherapy may be a rational form of intervention for some patients with pervasive developmental disorders (PDDs). The purpose of this article is to describe what is known about medication treatment for these patients. Methods.Published papers regarding the pharmacotherapy of PDDs were collected and reviewed. For each study, particular attention was paid to ascertaining patient characteristics, the medication doses employed, and medication tolerability.Results. There is evidence of varying methodological rigor to suggest that several medications may have a role in the treatment of patients with PDDs. However, to date, few randomized double-blind treatment studies have been published. In addition, there is very little known about the long-term safety of many of these agents in this patient population.Conclusions. Some patients with PDDs may benefit acutely from pharmacotherapy. Many marketed psychotropic agents that putatively hold promise for these patients have not been rigorously studied. More short-term and long-term research regarding the pharmacotherapy of patients with PDDs is needed.

show abstract

“…12,16,17 In addition, venlafaxine, a selective serotonin/norepinephrine inhibitor, has shown a positive effect on attention span and selfdestructive behavior in some patients with ASD. 18,19 Stimulants seemed to be less effective and poorly tolerated by most patients with ASD. 20 Despite the scarce knowledge about the function of noradrenergic neurotransmission in the pathogenesis of ASD and limited use of noradrenergic agents, atomoxetine, a selective norepinephrine inhibitor (NRI), exhibited a beneficial effect in ADHD-like symptoms in patients with ASD.…”

mentioning

confidence: 95%

Reboxetine Treatment for Autistic Spectrum Disorder of Pediatric Patients With Depressive and Inattentive/Hyperactive Symptoms

Golubchik¹,

Sever²,

Weizman³

2013

Clinical Neuropharmacology

View full text Add to dashboard Cite

show abstract

Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms

Cited by 47 publications

References 20 publications

The association of ADHD symptoms to self-harm behaviours: a systematic PRISMA review

The association of ADHD symptoms to self-harm behaviours: a systematic PRISMA review

Recent Advances in the Pharmacological Treatment of Pervasive Developmental Disorders

Reboxetine Treatment for Autistic Spectrum Disorder of Pediatric Patients With Depressive and Inattentive/Hyperactive Symptoms

Contact Info

Product

Resources

About